Vitamin E supplementation in people with cystic fibrosis

Okebukola, Peter O; Kansra, Sonal; McCabe, Helen

doi:10.1002/14651858.cd009422

Cited by 13 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The general recommendation of the UK Cystic Fibrosis Trust Nutrition Working Group is regular estimation of serum vitamin E (in addition to lipid ratio) levels to guide vitamin E supplementation of up to 100 mg to 200 mg daily depending on the age of the individual (UK Cystic Fibrosis Trust 2002). This is an updated version of a previous review (Okebukola 2011;.…”

Section: Why It Is Important To Do This Reviewmentioning

confidence: 97%

Vitamin E supplementation in people with cystic fibrosis

Okebukola

Kansra

Barrett

2017

Cochrane Database of Systematic Reviews

Self Cite

View full text Add to dashboard Cite

Background People with cystic fibrosis are at an increased risk of fat-soluble vitamin deficiency including vitamin E. Vitamin E deficiency can cause a host of conditions such as haemolytic anaemia, cerebellar ataxia and cognitive di iculties. Vitamin E supplementation is widely recommended in cystic fibrosis and aims to ameliorate this deficiency. This is an updated version of the review. Objectives To determine the e ects of any level of vitamin E supplementation on the frequency of vitamin E deficiency disorders in people with cystic fibrosis. Search methods We searched the Cochrane Group's Cystic Fibrosis Trials Register and also searched international trial registers for any ongoing clinical trials that were not identified during our register search.

show abstract

Section: Why It Is Important To Do This Reviewmentioning

confidence: 97%

Vitamin E supplementation in people with cystic fibrosis

Okebukola

Kansra

Barrett

2017

Cochrane Database of Systematic Reviews

Self Cite

View full text Add to dashboard Cite

show abstract

“…Regarding human use, there is no standardization about vitamin E dose neither in oral intake [14,15] nor in skin formulations [10,19,20]. Although its deficiency in adults is unusual [4], its oral intake may be recommended in cystic fibrosis patients [21]. Oral supplementation is equally used to reduce ultraviolet damage to skin [14,15].…”

Section: Vitamin E Isoforms and Derivativesmentioning

confidence: 99%

Vitamin E and Derivatives in Skin Health Promotion

Santos¹,

Tavares²,

Barradas³

2021

Vitamin E in Health and Disease - Interactions, Diseases and Health Aspects

View full text Add to dashboard Cite

Vitamin E is fundamental for a proper function of human cells. Mostly obtained from vegetable oils, it has antioxidant and non-antioxidant actions. At times, its oral intake or skin application are employed. Oral intake is recommended in some cases. Differently, the topical application is a part of daily skin routine. Both in oral or in topical formulations, it is employed in its isoforms or derivatives. Tocopherols and tocotrienols are isoforms while derivatives are synthetic forms. In pharmaceutical and cosmetic formulations, vitamin E and its derivatives are widely used due to its antioxidant and photoprotective properties. However, the clinical success treatment is often impaired by its low skin penetration, high lipophilicity, and chemical instability. A rational formulation design in the development of novel vitamin E dosage forms is required. In this chapter, the most successful and innovative approaches towards Vitamin E and its derivatives loaded in formulations for skin health promotion are reviewed. Conventional and nanoparticle-based formulations enable vitamin E chemical stabilization, and they are suitable vehicles for its release on the skin. Further, nano-sized carriers can increase vitamin E content in formulations as well as favor its skin penetration.

show abstract

“…Antioxidants may be of benefit in treating osteoporosis associated with COPD [2,5]. A systematic review of vitamin E supplementation reported no clinical benefits in patients with cystic fibrosis [57]. Some trials report improvements in clinical outcomes with antioxidant supplements in respiratory diseases.…”

Section: Naturally Occurring Dietary Antioxidant Supplementsmentioning

confidence: 99%

Targeting oxidant-dependent mechanisms for the treatment of respiratory diseases and their comorbidities

Thomson

2018

Current Opinion in Pharmacology

View full text Add to dashboard Cite

Oxidative stress is implicated in the pathogenesis of respiratory diseases, such as COPD and its comorbidities, asthma, idiopathic pulmonary fibrosis and radiation pneumonitis. Antioxidants drugs, such as small molecule thiols, nuclear erythroid-2 related factor 2 activators and catalytic enzyme mimetics have been developed to target oxidant-dependent mechanisms. The therapeutic effects of antioxidants have been generally disappointing. A small number of antioxidants are approved for clinical use, such as the small molecule thiol N-acetyl-l-cysteine for chronic obstructive pulmonary disease, and in the United States, the superoxide dismutase mimetic AEOL 10150 for severe radiation pneumonitis. The future use of antioxidants for the treatment of chronic respiratory diseases may require a precision medicine approach to identify responsive patients.

show abstract

Vitamin E supplementation in people with cystic fibrosis

Cited by 13 publications

References 29 publications

Vitamin E supplementation in people with cystic fibrosis

Vitamin E supplementation in people with cystic fibrosis

Vitamin E and Derivatives in Skin Health Promotion

Targeting oxidant-dependent mechanisms for the treatment of respiratory diseases and their comorbidities

Contact Info

Product

Resources

About